Klotho Neurosciences (KLTO) Price to Earnings Ratio
The development of Klotho Neurosciences Inc (KLTO) relies on unique patents for the application of the Klotho protein and rigorous FDA oversight. Drug delivery is based on strict adherence to temperature controls during transportation. The market value dynamics of the asset with the -3.10 indicator underscore the brand's status as a leading developer of brain anti-aging treatments, which is generating significant interest within the medical community.
Analytical breakdowns for Klotho Neurosciences Inc
- price and consensus price forecast:
- market capitalization details:
- book capitalization information:
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Klotho Neurosciences Inc|KLTO - Long-Term Debt to Equity|Current Liabilities to Capital ANEW Medical, Inc.|KLTO - Company Total Debt|Debt to Net Assets Ratio Klotho Neurosciences Inc|KLTO - Company Long-Term Debt|Company Short-Term Indebtedness Klotho Neurosciences|Immediate Liquidity anewmeds.com
- business earnings and investment ratios data:
KLTO - Net Income|Projected Future Earnings Klotho Neurosciences Inc|KLTO - Price to Earnings Ratio|Future Price to Earnings Multiple ANEW Medical, Inc.|KLTO - Price/Earnings to Growth Ratio|Company Value to EBITDA Klotho Neurosciences Inc|KLTO - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Klotho Neurosciences|KLTO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months anewmeds.com|KLTO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Klotho Neurosciences Inc
General company analysis:anewmeds.com - KLTO
For Klotho Neurosciences Inc (KLTO), which seeks dominance in the therapy of neurodegenerative diseases, this indicator reflects market expectations regarding the monetization of future developments. By analyzing the company's P/E ratio history, an investor assesses the current premium for future earnings, which allows for the determination of the capitalization's vulnerability to macroeconomic shocks and regulatory risks within the neuropharmaceutical sector.
Analysis of competing companies
P/E Multiple biogen.com|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|Price to Earnings Ratio RGC (Regencell Bioscience Ltd)|Price to Earnings Ratio Axsome Therapeutics Inc AXSM|ACADIA Corp (ACAD) - Market Cap to Earnings|XENE: Price to Earnings Ratio|vikingtherapeutics.com - Market Price to Net Income Ratio|SUPN: P/E Multiple|Catalyst Pharma - Company Value to Net Income|Price to Earnings Ratio Denali Therapeutics Inc|Market Cap to Earnings Harmony Corp HRMY|Price to Earnings Ratio BHVN (Biohaven Ltd.)|AMLX (amylyx.com) - Company Value to Net Income|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|PRAX: Price to Earnings Multiple|Anavex Corp - P/E Multiple|Market Cap to Earnings CeriBell EEG|PRTA (prothena.com) - Price to Earnings Ratio|Alector (ALEC) - P/E Multiple|Price to Earnings Ratio Annexon|OMER: Company Value to Net Income|Price to Earnings Ratio Neurogene Corp (NGNE)|ACIU - Market Cap to Earnings|Price to Earnings Ratio Voyager Therapeutics VYGR|Business Payback Period neumoratx.com (NMRA)|Scilex - P/E Multiple|Tevogen Bio Holdings Inc. (TVGN) - Price to Earnings Ratio|ACOG: P/E Multiple|CGTX - Business Payback Period|IKT (Inhibikase Therapeutics) - P/E Multiple|Market Cap to Earnings cassavasciences.com SAVA|Price to Earnings Ratio Assertio Holdings, Inc. (ASRT)|coyatherapeutics.com - Price to Earnings Multiple|P/E Multiple VTGN (Vistagen)|OVID - Price to Earnings Ratio|Acumen Pharmaceuticals - P/E Multiple|Market Cap to Earnings cervomed.com|alteritytherapeutics.com (ATHE) - Price to Earnings Ratio|CLNN - Business Payback Period|Price to Earnings Ratio PEPG|JUNS: Company Value to Net Income|P/E Multiple RLMD|Business Payback Period annovisbio.com|Price to Earnings Ratio Grace Therapeutics GRCE|AIFF: Price to Earnings Multiple|NeuroSense Therapeutics, Ltd. - P/E Multiple|Reviva Pharmaceuticals, Inc. (RVPH) - Price to Earnings Ratio|metaviatx.com (MTVA) - Price to Earnings Ratio|neuraxis.com (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical Technologies, Inc.|Price to Earnings Ratio PASG|Price to Earnings Ratio NEUP (Neuphoria Therapeutics Inc.)|Market Price to Net Income Ratio NERV|Price to Earnings Ratio Athira Pharma, Inc. ATHA|addextherapeutics.com (ADXN) - Market Cap to Earnings|ALZN - Price to Earnings Ratio|CYCN (Cyclerion Therapeutics) - Price to Earnings Multiple|PTIX: P/E Multiple|Market Cap to Earnings Pasithea Therapeutics Corp. (KTTA)|Price to Earnings Ratio CRGT|P/E Multiple avenuetx.com|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|CARA (Cara Therapeutics Inc.) - Company Value to Net Income|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|Eliem Therapeutics, Inc. (ELYM) - Market Cap to Earnings|ITCI - Price to Earnings Ratio|LBPH - P/E Multiple|Marinus Pharmaceuticals, Inc. (MRNS) - Price to Earnings Ratio|NKGN (NKGen Biotech Inc) - Price to Earnings Ratio|Price to Earnings Ratio NeuroBo|Market Cap to Earnings Sage Therapeutics Inc SAGE|Price to Earnings Ratio SNPX (Synaptogenix, Inc.)|Market Price to Net Income Ratio TRVN|P/E Multiple VIGL (Vigil Neuroscience, Inc.)|Company Value to Net Income WENA|CERE - Price to Earnings Ratio
